S 1906
114th Congress
Senate
Health
Drug safety, medical device, and laboratory regulation
Drug therapy
Income tax credits
Prescription drugs
User charges and fees
Orphan Drug Fairness Act
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 30, 2015
Read twice and referred to the Committee on Finance.
Jul 30, 2015
Introduced in Senate
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Plain-English summary
Orphan Drug Fairness Act
This bill amends the Patient Protection and Affordable Care Act (PPACA) to exclude sales of any drug or biological product approved by the Food and Drug Administration solely for rare diseases or conditions (orphan drug) from the calculation of the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million.
This Act is effective as if included in PPACA.
What's happening now
Read twice and referred to the Committee on Finance.
Related & companion bills
1
Bill text
1 version
- Introduced in Senate Formatted Text PDF Formatted XML
Committees of jurisdiction
1
Cosponsors
1
Cite this page
U.S. Congress. (2026). S. 1906: Orphan Drug Fairness Act. 114th Congress. Open America. https://openamerica.io/bill/114-S-1906/
"S. 1906: Orphan Drug Fairness Act." 114th Congress, 2026, Open America, https://openamerica.io/bill/114-S-1906/.
S. 1906, 114th Cong. (2026), https://openamerica.io/bill/114-S-1906/.
[S. 1906: Orphan Drug Fairness Act](https://openamerica.io/bill/114-S-1906/)